Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice

Elisa Santambrogio, Mattia Novo, Delia Rota-Scalabrini, Umberto Vitolo

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Elderly patients represent a consistent portion of new diagnoses of B cell Non-Hodgkin Lymphoma (B-NHL). The treatment approach in this setting can be challenging for clinicians due to treatment toxicities and patients' comorbidities to deal with. Immunochemotherapy still represents the main option in the front-line setting for diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), with different options to choose depending on patient characteristics. In the last decade, a number of new drugs and combinations have been investigated, demonstrating efficacy and safety even in the older population and extending the spectrum of treatment choices for this setting.

AREAS COVERED: This article reviews the majority data in literature on immunochemotherapy regimens and chemo-free approaches available for DLBCL, FL, and MCL in the elderly, both in front-line and relapse/refractory setting, the incoming drugs and how to identify the best option for each patient.

EXPERT OPINION: The therapeutic approach for elderly B-NHL is challenging and a tailored approach guided by a geriatric assessment is mandatory, in order to optimize efficacy and minimize treatment-related toxicities. The more extended use of biological drugs may potentially lead to prolonged survival with reduction of toxicities and improved quality of life.

Original languageEnglish
Pages (from-to)851-869
Number of pages19
JournalExpert Review of Hematology
Issue number8
Publication statusPublished - Aug 2020


Dive into the research topics of 'Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice'. Together they form a unique fingerprint.

Cite this